Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr Reddy’s Laboratories ( (RDY) ) has provided an announcement.
Dr. Reddy’s Laboratories has been under scrutiny since an anonymous complaint in 2020 alleged improper payments to healthcare professionals in Ukraine and potentially other countries, raising possible violations of U.S. anti-corruption laws such as the Foreign Corrupt Practices Act. The company disclosed the matter to U.S. and Indian regulators, engaged a U.S. law firm to conduct a detailed investigation, and warned investors that the probe could lead to enforcement actions and sanctions.
On February 23, 2026, the U.S. Securities and Exchange Commission informed Dr. Reddy’s that it had concluded its investigation and did not intend to recommend enforcement action against the company at this time. While the SEC stressed that the notice does not amount to exoneration or a guarantee that no future action will result, the outcome reduces an immediate regulatory overhang for the drugmaker and provides some clarity to stakeholders who had been tracking the long-running anti-corruption inquiry.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company focused on developing, manufacturing and marketing generic medicines and active pharmaceutical ingredients. The company serves regulated markets including the U.S., India and Europe, and its shares are listed in Mumbai, on the National Stock Exchange of India and on the New York Stock Exchange.
Average Trading Volume: 1,517,229
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.74B
Learn more about RDY stock on TipRanks’ Stock Analysis page.